Gritstone Oncology's neoantigen-based immunotherapies for precision and off-the-shelf cancer treatment show promise in early safety trials.
The collaboration will test the effects of using human microbiome-derived bacteria alongside immune checkpoint inhibitor nivolumab to treat advanced metastatic cancers.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.
Researchers have shown that the use of antibiotics in the weeks leading up to immunotherapy may lessen a patients' response to the treatment.
A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.
The study failed to show Opdivo plus chemoradiation significantly improves PFS compared to standard of care in MGMT-methylated glioblastoma.
A prospective study in 35 advanced melanoma patients found that response to combined Yervoy and Opdivo was correlated with the three markers.
The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.
H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.